Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Protease inhibitor
Atazanavir is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). -
HIV Protease inhibitor
Atazanavir is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). -
HIV Protease inhibitor
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease.Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. -
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
HIV Protease Inhibitor
Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. Saquinavir inhibits both HIV-1 and HIV-2 proteases.- Ernawati Arifin Giri-Rachman, .et al. , ACS Synth Biol, 2024, Feb 16; 13(2): 509-520 PMID: 38316139
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
-
HIV-1 protease inhibitor
Nelfinavir is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.- Joanna Ireland, .et al. , Front Microbiol, 2024, Mar 20:15:1385775 PMID: 38572241
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
-
HIV Protease Inhibitor
Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. -
HIV protease inhibitor
Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. - Indinavir sulfate is a novel hydroxyaminopentane amide class of HIV-1 protease inhibitors.
- Amprenavir is an human immunodeficiency virus (HIV) protease inhibitor with IC50 of 14.6 ?? 12.5 ng/ml for wild-type HIV isolates
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
-
HIV protease inhibitor
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. -
HIV-1 RT inhibitor
Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate. -
HIV-1 maturation inhibitor
Bevirimat (MPC-4326, PA-457, YK-FH312) is a first-in-class HIV-1 maturation inhibitor that demonstrates high potency in cell culture and has shown clinical efficacy in HIV-1-infected patients.- Mingzhang Wang, .et al. , Nat Commun, 2017, 8: 1779 PMID: 29176596
-
HIV protease inhibitor
Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. -
HIV-1 attachment inhibitor
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.- Min Li, .et al. , J Infect Dis, 2025, Jul 16:jiaf373
- Min Li, .et al. , Nat Commun, 2020, 11: 4051 PMID: 32792548
-
HIV-1 attachment inhibitor
BMS-663068 tris is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. -
HIV protease inhibitor
Fosamprenavir Calcium Salt is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir, with improved solubility over the parent molecule and a potential for reduced pill burden on current dosing regimens; GW433908G is the calcium salt of the prodrug. -
HIV protease inhibitor
Tipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates. -
HIV fusion inhibitor
Enfuvirtide Acetate (T-20) is a 36 amino acid peptide corresponding to a region of gp41, the transmembrane subunit of HIV-1 envelope protein. -
HIV maturation inhibitor
GSK2838232-isomer is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection.
-
HIV-1 maturation inhibitor
GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor. CAS: 1392312-45-6 (free base) 2023808-13-9 (HCl) 2023798-97-0 (HCl hydrate) 2097784-79-5 (oxalate) -
HIV capsid inhibitor
CA inhibitor 1 (GS-6207 analog) is a potent HIV capsid inhibitor for HIV inhibition. -
HIV infection inhibitor
HIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927. -
HIV-1 reverse transcriptase inhibitor
beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor. -
antioxidant agent
Rosamultin is a 19 α-hydroxyursane-type triterpenoid isolated from Potentilla anserina L. Rosamultin has inhibitory effects against HIV-1 protease. Rosamultin has the potential for treating H2O2-induced oxidative stress injury through its antioxidant and antiapoptosis effects. -
human immunodeficiency virus protease inhibitor
Des(benzylpyridyl) Atazanavir is a metabolite of Atazanavir, a human immunodeficiency virus protease inhibitor. -
HIV Protease Inhibitor
Cytochalasin A is a cell-permeable fungal toxin that is an oxidized derivative of cytochalasin B. Cytochalasin A is an inhibitor of HIV-1 protease (IC50=3 μM) and inhibits actin polymerization and interferes with microtubule assembly by reacting with sulfhydryl groups. Antibiotic and fungicidal activitives. -
HIV Protease Inhibitor
Indinavir is a selective inhibitor of HIV-1 protease, displaying a Ki value of 0.54 nM, making it a potent antiviral agent. In addition to its primary role in HIV treatment, Indinavir has demonstrated anticancer properties by inhibiting matrix metalloproteinases (MMPs) and promoting anti-angiogenic effects, alongside inducing apoptosis in cancer cells. Furthermore, Indinavir has shown inhibitory activity against the SARS-CoV 3CL protease, expanding its potential applications in viral research. -
HIV Protease Inhibitor
Indinavir sulfate ethanolate is a selective inhibitor of HIV-1 protease, demonstrating a potent Ki of 0.54 nM for the target enzyme. Beyond its antiviral activity, this compound has shown potential in anticancer research through the inhibition of MMPs-2 activation, anti-angiogenic effects, and promotion of apoptosis. Additionally, Indinavir sulfate ethanolate acts as an inhibitor of the SARS-CoV 3CLpro enzyme, highlighting its diverse biological activity and relevance in multiple research applications. -
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
HIV protease Inhibitor
Telinavir is a potent and selective inhibitor of HIV protease. It effectively inhibits various strains of HIV-1, HIV-2, and simian immunodeficiency virus at EC50 values of 26 ng/mL (43 nM). With a high degree of protein binding in human plasma and minimal partitioning into erythrocytes, Telinavir serves as a valuable tool in HIV research and therapeutic development. -
HIV protease inhibitor
SB 204144 is a potent inhibitor of HIV protease, disrupting the proteolytic processing of viral polyproteins and hindering the maturation of infectious HIV particles. This compound is valuable for research on HIV pathogenesis and immune system diseases, enabling studies on antiviral effects and the development of new therapeutic strategies against HIV. Its application in virology underlines its relevance in understanding and combating HIV infection. -
HIV Protease Inhibitor
DMP-851 is a potent cyclic urea inhibitor of HIV protease, exhibiting a Ki of 0.021 nM. It demonstrates significant antiviral activity against both laboratory strains of HIV-1 and HIV-2, as well as primary clinical isolates that are resistant to Zidovudine. This compound serves as an important tool for research into HIV treatment and resistance mechanisms. -
HIV Protease Inhibitor
BILA 1906 BS is a potent HIV protease inhibitor that disrupts HIV-1 replication by inhibiting the protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. This compound effectively blocks the maturation of p24 proteins in wild-type HIV-1, thereby impairing polyprotein processing and viral maturation. BILA 1906 BS is valuable for research focused on human immunodeficiency virus type 1 (HIV-1) infection and its associated cellular mechanisms. -
HIV Protease Inhibitor
JE-2147 is a potent dipeptide inhibitor of HIV protease, exhibiting a Ki value of 0.33 nM for HIV-1 protease. This compound demonstrates effective antiviral activity against a broad range of HIV strains, including HIV-1, HIV-2, simian immunodeficiency virus, and various clinical isolates of HIV-1 in vitro. JE-2147 serves as a valuable tool for research into HIV protease inhibition and the development of antiretroviral therapies. -
HIV Protease Inhibitor
CGP 53820 is a potent inhibitor of HIV protease, demonstrating Ki values of 9 nM for HIV-1 protease and 53 nM for HIV-2 protease. This compound effectively disrupts the enzymatic activity critical for the replication of HIV, making it a valuable tool in AIDS research and the study of antiretroviral therapies. Its specificity and efficacy support investigations into HIV resistance and the development of novel therapeutic strategies. -
HIV Protease Inhibitor
P-1946 is a potent HIV protease inhibitor demonstrated to have a human HIV-1 protease Ki of 2.600 nM. It exhibits strong and selective in vitro antiviral activity, remaining effective against HIV isolates that have developed resistance to existing protease inhibitors. P-1946 is suitable for research applications focused on human immunodeficiency virus type 1 (HIV-1) infection. -
HIV Protease Inhibitor
BMS 186318 is a potent HIV protease inhibitor that plays a critical role in blocking viral replication by interfering with the proteolytic processing of viral polyproteins. This compound demonstrates enhanced anti-HIV efficacy when used in conjunction with reverse transcriptase inhibitors and additional protease inhibitors. BMS 186318 is ideal for applications in antiviral research, contributing to the development of effective therapeutic strategies against HIV. -
HIV Protease Inhibitor
MK-8718 is a potent and orally bioavailable HIV protease inhibitor that features a morpholine aspartate binding group. This compound effectively inhibits the activity of HIV protease, making it a valuable tool for studying HIV infection and antiretroviral therapy mechanisms. Its application in research may enhance the understanding of HIV replication and contribute to the development of novel therapeutic strategies.
